Entereg Related Published Studies
Well-designed clinical trials related to Entereg (Alvimopan)
A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. [2011.02]
A randomized, placebo-controlled phase 3 trial (study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. [2011.02]
Alvimopan for the management of postoperative ileus after bowel resection: characterization of clinical benefit by pooled responder analysis. [2010.09]
Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway. [2008.11]
Clinical trial: alvimopan for the management of post-operative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study. [2008.08.01]
Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. [2008.07.15]
Postoperative ileus-related morbidity profile in patients treated with alvimopan after bowel resection. [2007.04]
Other research related to Entereg (Alvimopan)
Economic analysis of alvimopan for prevention and management of postoperative
ileus. [2012]
The effect of alvimopan on recovery after laparoscopic segmental colectomy. [2011.06]
Alvimopan use in laparoscopic and open bowel resections: clinical results in a large community hospital system. [2010.11]
Alvimopan Use in Laparoscopic and Open Bowel Resections: Clinical Results in a Large Community Hospital System(November). [2010.09.21]
The effects of a short course of antibiotics on alvimopan and metabolite pharmacokinetics. [2010.03]
Alvimopan for the management of postoperative ileus after bowel resection:
characterization of clinical benefit by pooled responder analysis. [2010]
Economic analysis of alvimopan in North American Phase III efficacy trials. [2009.08.01]
Alvimopan for postoperative ileus. [2009.07.15]
Management of postoperative ileus: focus on alvimopan. [2008.10]
Alvimopan and COX-2 inhibition reverse opioid and inflammatory components of postoperative ileus. [2008.06]
Clinical trial: alvimopan for the management of postoperative ileus after abdominal surgery: results of an international randomised, double-blind, multicentre, placebo-controlled clinical study. [2008.03.28]
Mosapride in gastrointestinal disorders. [2008]
Alvimopan accelerates gastrointestinal recovery after bowel resection regardless of age, gender, race, or concomitant medication use. [2007.10]
Alvimopan: a peripherally acting mu-opioid receptor antagonist. [2007.09]
Patterns of gastrointestinal recovery after bowel resection and total abdominal hysterectomy: pooled results from the placebo arms of alvimopan phase III North American clinical trials. [2007.07]
Alvimopan, for postoperative ileus following bowel resection: a pooled analysis of phase III studies. [2007.03]
Meta-analysis: Alvimopan vs. placebo in the treatment of post-operative ileus. [2007.01.01]
Other possibly related research studies
Gastrointestinal recovery after laparoscopic colectomy: results of a prospective, observational, multicenter study. [2010.03]
Pharmacologic options to prevent postoperative ileus. [2009.09]
Peripherally acting mu-opioid receptor antagonists and postoperative ileus: mechanisms of action and clinical applicability. [2009.06]
Pharmacological management of postoperative ileus. [2009.04]
Opioid receptors in the gastrointestinal tract. [2009.06.05]
Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus. [2009.04.04]
New approaches to the treatment of opioid-induced constipation. [2008.08]
Efficacy and safety of mu-opioid antagonists in the treatment of opioid-induced bowel dysfunction: systematic review and meta-analysis of randomized controlled trials. [2008.09]
[News from the cochrane library: mu opioid antagonists for opioid-induced bowel dysfunction] [2008.09]
Methylnaltrexone, a new peripherally acting mu-opioid receptor antagonist being evaluated for the treatment of postoperative ileus. [2008.09]
Mu-opioid antagonists for opioid-induced bowel dysfunction. [2008.04.16]
Gateways to clinical trials. [2008.01]
New therapies in the treatment of postoperative ileus after gastrointestinal surgery. [2008.01]
Gateways to clinical trials. [2007.10]
The involvement of the mu-opioid receptor in gastrointestinal pathophysiology: therapeutic opportunities for antagonism at this receptor. [2008.01]
Gateways to clinical trials. [2007.09]
Opioid-induced bowel dysfunction. [2008.01]
Emerging pharmacologic options for treating postoperative ileus. [2007.10.15]
Mu opioid receptor antagonists: recent developments. [2007.11]
Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review. [2007.11]
Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus. [2007]
Cancer-related constipation. [2007.07]
Gateways to clinical trials. [2007.04]
Novel and alternative therapies for childhood constipation. [2007.06]
Treatment of opioid-induced gut dysfunction. [2007.02]
Current and future therapies for chronic constipation. [2011.02]
Opioid-induced constipation: challenges and therapeutic opportunities. [2011.05]
Opioid antagonists for prevention and treatment of opioid-induced gastrointestinal effects. [2010.10]
Novel opioid antagonists for opioid-induced bowel dysfunction. [2011]
|
